New Delhi, April 4 -- The Indian Pharmacopoeia Commission ( IPC), which acts as the National Coordination Centre for the Pharmacovigilance Programme of India (PvPI) and provides evidence-based research to CDSCO, will be monitoring the safety of weight loss drugs. The Indian Pharmacopoeia Commission will be compiling a report of adverse events which are associated with the GLP-1 drugs.

According to the Official sources, the IPC has started the regular monitoring of adverse events of weight-loss drugs through the PvPI system: "IPC is regularly monitoring the adverse events of such drugs through the passive surveillance system under PvPI."

The official further said that they will be interacting regularly with the manufacturers to monitor t...